DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1939)

Alzheimer's Disease | Special Topics | Detailed, Expanded Analysis (US & EU) - Special Topics

Alzheimer's Disease | Special Topics | Detailed, Expanded Analysis (US & EU) - Special Topics

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – July 2019

Given the seemingly constant failure of emerging disease-modifying therapies (DMTs) in Alzheimer's disease (AD) that target the amyloid cascade, industry has gradually expanded its focus to include a growing pool of novel strategies that target tau, the other pathological hallmark of AD. Though most tau-targeted therapies are in early-phase (I or II) development, many of them are sponsored by large pharma with a strong neurology/AD presence (e.g., AbbVie, Janssen, Merck, Biogen). Dissecting the ongoing clinical development programs—mechanism of action (stabilization, aggregation, and/or phosphorylation of tau), supportive evidence/clinical data, trial design, etc.—will help current pioneers and new players in this space understand the evolving competitive landscape. Simultaneously, because biomarkers will play an increasingly important role in the screening of patients and clinical assessment of DMTs, it is critical to understand ongoing developments in this arena and neurologists’ perspectives on the future of biomarkers in AD.

Questions Answered

  • What is the landscape for emerging tau-targeted therapies and biomarkers in AD? What are the key features in the ongoing clinical trials?
  • What are interviewed KOLs’ opinions about new tau-targeted therapies in development, and the role of tau vs. amyloid in the pathology of AD?
  • How do experts in the field believe these agents compare with the late-phase anti-Aβ therapies?
  • How is the role of molecular biomarkers in AD research evolving?

Product Description

DRG’s Special Topics reports assess key trends in dynamic disease areas. This report on AD will help developers gain needed insight into the rapidly growing area of tau and biomarker research in AD that could shape the future of this market.

Geographies: United States

Primary research: Interviews with 15 neurologists/tau thought leaders across the United States and Europe

Key drugs covered: Clinical-stage tau compounds, including LMTX, AADvac1, ABBV-8E12, LY3303560, gosuranemab, BIIB-076, BIIB-080

Key nonmotor symptoms covered: Dementia, orthostatic hypotension, psychosis, sleep disruption, and others

Key insights provided:

  • Pipeline review: tau therapies and biomarkers
  • KOLs’ awareness and perceptions of key anti-tau therapies
  • KOLs’ opinions of discrete tau targets
  • Expectations from tau-targeted therapies vs. other disease-modifying approaches
  • KOLs’ insight on biomarkers

Table of contents

  • Detailed, Expanded Analysis (US & EU) - Special Topics
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Jonathan Searles
  • Jonathan ;Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, ;Searles received a degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Purchase Report

Recent reports:
You may also be interested in: